To include your compound in the COVID-19 Resource Center, submit it here.

CFDA releases submission guidelines for anti-PD-1, PD-L1 mAbs

China FDA's Center for Drug Evaluation (CDE) said single-arm trials

Read the full 108 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE